Recent Finacing
Recent Raise
Ra Pharmaceuticals develops peptide-like macrocycle therapeutics from its Extreme Diversity platform, focusing on complement C5 inhibitors including subcutaneous RA101495 for PNH and a broader complement-targeted pipeline; partners with MSD.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
